We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients.
- Authors
Hatch, Kenneth D.; Beecham, Jackson B.; Blessing, John A.; Creasman, William T.; Hatch, K D; Beecham, J B; Blessing, J A; Creasman, W T
- Abstract
One hundred five patients with Stage III or IV epithelial ovarian cancer whose disease had persisted or recurred after primary surgery and first-line chemotherapy were given tamoxifen (20 mg orally twice daily) and evaluated for response. Eighteen percent of the patients responded: 10% demonstrated a complete response (CR) and 8% showed a partial response (PR). Thirty-eight percent of the patients had short-term disease stabilization. CR had a median duration of 7.5 months, with the longest lasting 17 months. For patients with PR or stable disease, the median duration of response was 3 months (maximum duration, 9 months). When estrogen receptors of tumor tissue from patients demonstrating CR were evaluated, eight of nine (89%) had elevated estrogen receptor levels. This contrasts with patients who had stable or progressive disease as only 59% of them had measurable estrogen receptors (P = 0.16).
- Publication
Cancer (0008543X), 1991, Vol 68, Issue 2, p269
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O